Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 67   

Articles published

JNJ 105.55 -1.26 (-1.18%)
price chart
J.&J. Names Outsider to Run Its Troubled Consumer Unit
Johnson & Johnson named an outsider on Thursday to fill a top leadership role overseeing its troubled consumer health unit, a break from the company's longstanding tradition of promoting executives from within.
Johnson & Johnson Hires Former Bayer Exec To Combat Mounting Porblems  ValueWalk
J&J picks Bayer AG exec to solve its consumer product mess  FiercePharma
Related articles »  
Johnson & Johnson to open life science centres
Johnson & Johnson is to open four life science �innovation centres� as it decentralises decisions on investment and partnerships to boost productivity.
Johnson & Johnson sets up SF center  San Francisco Chronicle
Johnson & Johnson Announces Plans to Establish Innovation Centers  PR Newswire (press release)
Related articles »  
Lawyers in Risperdal case argue Johnson & Johnson's CEO should be called to ...
Johnson & Johnson's top executive should be forced to testify about claims that the company illegally marketed the antipsychotic drug Risperdal, which allegedly caused boys to grow breasts, lawyers for a teenager suing the drugmaker said in a court filing.
J&J's Alex Gorsky testify? Much too busy....on the other side of the ...  Philadelphia Inquirer (blog)
Related articles »  
Johnson & Johnson Launches Be Vital Challenge to Reward College Student ...
NEW BRUNSWICK, N.J., Sept. 18, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) is launching a challenge to reward college student organizations for their effort in taking care of the world we share.
Related articles »  
Johnson & Johnson settles on first day of Philly Risperdal trial
A jury was picked and the trial was about to begin Monday morning in Philadelphia Common Pleas Court when Johnson & Johnson's Janssen Pharmaceuticals subsidiary settled a lawsuit with a Texas man who said he grew breasts as a child after being ...
J&J Sees Male Breasts And Quickly Settles Risperdal Suit  Forbes
J&J Settles Pa. Risperdal Lawsuit On Opening Day of Trial  Law360 (subscription)
Related articles »  
Procter & Gamble Takes Over #11 Spot From Johnson & Johnson
But comparing market capitalization (factoring in those share counts) creates a true �apples-to-apples� comparison of the value of two stocks.
Johnson & Johnson Report: 54% of Hospitals Say Green Attributes Important in ...
More than one-third (35 percent) of hospitals surveyed switched suppliers to gain access to sustainable health-care products, according to a new report by Johnson & Johnson that finds hospitals are placing greater emphasis on �green� products used in ...
Future Impact of Environmental Scorecards, Hospital Global Purchasing ...  CSRwire.com (press release)
Related articles »  
Johnson & Johnson - Life After The Patent Cliff?
Johnson & Johnson (NYSE:JNJ) saw the patents for its antibiotic, Levaquin (Floxin), and its ADHD/ADD drug, Concerta, expire in 2011.
Related articles »  
Johnson & Johnson plans intravenous Simponi rheumatoid arthritis drug
Janssen Biotech Inc. has submitted a biologics license application to the Food and Drug Administration requesting approval of an intravenous formulation of Simponi for the treatment of adults with moderately to severely active rheumatoid arthritis.
Related articles »  
$0 shareholder derivative settlement in Johnson & Johnson
Alison Frankel recently asked whether it's the end of "money-for-nothing" class actions. The Center for Class Action Fairness is putting that question to the test in In re Johnson & Johnson Shareholder Derivative Litigation by asking the District of ...